TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06021444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DKM420
Description: A total of 3 doses will be applied at a dose of 2 mL over 3 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conjuran
Description: A total of 3 doses will be applied at a dose of 2 mL over 3 weeks.
Study: NCT00552838

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Academic Detailing by the Antimicrobial Utilization Team (AUT)
Description: Physicians caring for patients who were prescribed one of three antimicrobials were randomly assigned to academic detailing by the AUT. The AUT would review the antimicrobial prescription and provide consultation to the ordering physician if the prescription is appropriate and provide feedback on a better alternative if inappropriate.
Study: NCT04358562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: If persistence of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: If persistence of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: If clearance of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment
Study: NCT02345343

Intervention type: DRUG
Intervention: Apixaban
Study: NCT00145327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Zoledronic Acid 5 mg in 100 mL physiologic 0.9% normal saline for intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Zoledronic Acid 5 mg in 100 mL physiologic 0.9% normal saline for intravenous infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mL physiologic 0.9% normal saline for intravenous infusion.
Study: NCT01283386

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorambucil
Description: 10 mg/m\^2 orally on Days 1-7 of each 28-day cycle for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 150 mg/m\^2 IV or orally on Days 1-3 of each 28-day cycle for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 20 mg/m\^2 IV or 32 mg/m2 orally Days 1-3 of each 28-day cycle for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV on Day 1 of Cycle 1; 500 mg/m2 IV on Day 1 of Cycles 2-6 (28-day cycles)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m2 IV on Day 1 of Cycle 1; 500 mg/m2 IV on Day 1 of Cycles 2-6 (28-day cycles)
Study: NCT04027946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMB-100
Description: Participants will receive LMB-100 on days 1, 3 and 5 of a 21-day cycle for up to 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Participants will receive pembrolizumab on day 1 of each subsequent 21-day cycle.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mesothelin Expression
Description: Testing for mesothelin expression performed at screening

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TrueSight Oncology 500
Description: Testing for ROS oncogene 1 (ROS1) gene, anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) variations performed at screening.
Study: NCT01320098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-Based Parenting Program
Description: The Home-Based Parenting Program aims to improve impulsive and oppositional behaviors in 3 and 4 year-olds. The program involves 8 home visits with a therapist. The visits focus on the skills listed below as a means of improving your child's behavior.~1. Helping you set developmentally appropriate goals for your child. One way we do this is by focusing on situations that occur naturally in your home. Another way is by having you engage in activities with your child that focus on improving attention and the ability to delay.~2. Increasing the quality and quantity of positive interactions between you and your child~3. Changing the way you respond to your child's inappropriate behaviors so as to reduce the frequency of negative interactions.~4. Improving your parenting skills. This program also includes between-session homework tasks so that you can practice the skills you have learned throughout the week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic-Based Parenting Program
Description: The Clinic-Based Parenting Program aims to improve ADHD symptoms by reducing noncompliance, which is common in children with ADHD. Parents learn how to help their child attend to and comply with requests and directions so as to improve compliance and attention.~The program involves 8 clinic visits with a therapist. Parents learn various parenting skills to help improve their child's behaviors.~Parents learn techniques and skills to promote positive interactions with their child, including:~1. Increasing the positive attention you give to your child.~2. Reducing the inappropriate use of commands, questions and criticisms.~3. Appropriate use of praise and physical attention (e.g., hugs) as rewards.~4. Actively ignoring minor, inappropriate behaviors. Parents also learn how to: increase compliance via clear instruction; respond to compliant and noncompliant behaviors; and create and use clear rules about appropriate and inappropriate child behaviors.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait-List Control Group
Description: If your child is randomized to the 8-week Wait-List group, you and your child will be asked to attend 2 assessment visits -1 screening/baseline visit and one 8 weeks later. These assessment visits will take place at our clinic. After completing the second assessment, you will receive your choice of either the home-based or clinic-based parenting program.
Study: NCT02458300

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nebulization of hypertonic saline
Description: application of hypertonic saline serum through a mask fogging or a box fogging

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nebulization of hypertonic saline
Description: application of hypertonic saline serum through a mask fogging or a box fogging

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged slow expiration technique (PSE)
Description: Passive expiratory aid implemented baby. the child is placed supine on a hard surface. Thoracoabdominal slow manual pressure that begins at the end of a spontaneous and continuous exhalation to residual volume is exercised. Oppose reaches 2 or 3 breaths. Vibrations can accompany the art. The goal is to achieve a greater expiratory volume.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient coughing Provocation (TP)
Description: Tp is based on the mechanism reflects cough induced by stimulation of the buttons on the wall of the trachea extrathoracic mechanoreceptors. The child is placed supine. A short pressure is done with the thumb on the tracheal conduit (in the sternal notch) at the end of inspiration, or at the beginning of expiration. With the other hand holding the abdominal region we prevent the dissipation of energy and make the explosion tussive more effective. It is done after the PSE.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: inspiratory maneuver to rhinopharyngeal cleaning DRR
Description: After the inspiratory reflection following the PSE, the TP or crying. At the end of expiratory time the child's mouth is closed with the back of his hand just finished his chest support, raising the jaw and forcing the child to an inspiration with the nose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Aspiration of secretions
Description: Suctioning with a probe by a vacuum system installed on the wall.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aspiration of secretions
Description: Suctioning with a probe by a vacuum system installed on the wall.
Study: NCT00894920

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: biotin
Description: capsule approximately 30 mcg daily 21 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: biotin
Description: capsule 300 mcg daily 21 days
Study: NCT01801527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation group
Description: Interventions will be based on to provide cardiovascular, mobility, strength and stretching exercises through telerehabilitation system
Study: NCT02205138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLOB® cells with ceramic scaffold
Description: Each patient will undergo a single administration of ALLOB®/ceramic scaffold mix into the lumbar interbody fusion site under anaesthesia
Study: NCT04393428

Intervention type: OTHER
Intervention: [TIMP-2]*[IGFBP-7]
Description: \[TIMP-2\]\*\[IGFBP-7\] mesurement in urine sample relicates of COVID-19 patients admitted to the Montpellier University Hospital
Study: NCT05951842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anesthetic method
Description: Patients will be assigned to one of the groups, TIVA group or Balanced anesthesia group. In TIVA group, anesthesia will be maintained by propofol and remifentanil infusion under target controlled infusion. In contrast, anesthesia will be maintained by sevoflurane and remifentanil infusion in the balanced anesthesia group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anesthetic method
Description: Patients will be assigned to one of the groups, TIVA group or Balanced anesthesia group. In TIVA group, anesthesia will be maintained by propofol and remifentanil infusion under target controlled infusion. In contrast, anesthesia will be maintained by sevoflurane and remifentanil infusion in the balanced anesthesia group.
Study: NCT03946410

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Invitation to screening
Description: Invitation to CVD screening with non contrast CT scanning, ABI measurement and blood tests

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Invitation to screening
Description: Invitation to CVD screening with non contrast CT scanning, ABI measurement and blood tests
Study: NCT00263562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid arm
Description: Day 1: Solumedrol 15 mg/kg (maximum 1 gram) Day 2: Prednisone 2mg/kg PO BID Day 3: Prednisone 2mg/kg PO daily Day 4: Prednisone 1mg/kg PO daily Day 5: Prednisone 1mg/kg PO daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients received normal saline in lieu of intravenously-administered methylprednisolone and placebo pills equal in number to the steroid pills received in the steroid arm
Study: NCT00069329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anakinra
Description: daily injection of subcutaneous injection
Study: NCT02707744

Intervention type: OTHER
Intervention: no intervention

Intervention type: OTHER
Intervention: no intervention
Study: NCT02811978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Participants will receive 1.3 mg/m\^2 bortezomib on Days 1, 4, 8, and 11 of a 3 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Participants will receive 1.3 mg/m\^2 bortezomib on Days 1, 4, 8, and 11 of a 3 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants will receive Dexamethasone at a dose of 20 mg PO on the day of and the day after bortezomib dosing (Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants will receive Dexamethasone at a dose of 20 mg PO on the day of and the day after bortezomib dosing (Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle).
Study: NCT01526369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Study: NCT03522168

Intervention type: DRUG
Intervention: Risperidone
Description: Medications prescribed as standard of care for Schizophrenia, Bipolar mania/acute treatment of manic and mixed episodes associated with Bipolar I disorder, Tourette's disorder, persistent (chronic) motor or vocal tic disorder and Irritability associated with autistic disorder

Intervention type: DRUG
Intervention: Aripiprazole
Description: Medications prescribed as standard of care for Schizophrenia, Bipolar mania/acute treatment of manic and mixed episodes associated with Bipolar I disorder, Tourette's disorder, persistent (chronic) motor or vocal tic disorder and Irritability associated with autistic disorder
Study: NCT02650349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Study: NCT04781465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality
Description: Dedicated virtual reality sessions.~* Duration 20 minutes per session.~* The virtual reality session will be supervised by a health professional trained in this tool after 1.5 hours of training by the team responsible for the equipment (use of the equipment, and use of the 20 minutes of VR). This supervising professional may be a doctor, an occupational therapist, a caregiver or any other health professional trained in the tool under this protocol.~* The exercises proposed will be standardized virtual reality exercises with the same exercises for all, but adapted to the level and abilities of each patient.
Study: NCT04613869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose Esketamine hydrochloride+Hydromorphone
Description: By adding different doses of esketamine to the postoperative analgesic pump, and the control group without adding this drug to observe the postoperative pain, anxiety and depression indicators of the surgical patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose Esketamine hydrochloride+Hydromorphone
Description: By adding different doses of esketamine to the postoperative analgesic pump, and the control group without adding this drug to observe the postoperative pain, anxiety and depression indicators of the surgical patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydromorphone
Description: No esketamine added
Study: NCT00986232

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live
Description: a single 0.5 mL subcutaneous injection of ProQuad (low, middle, or high dose) at Day 0 and Day 90

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live
Description: a single 0.5 mL subcutaneous injection of ProQuad (low, middle, or high dose) at Day 0 and Day 90

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live
Description: a single 0.5 mL subcutaneous injection of ProQuad (low, middle, or high dose) at Day 0 and Day 90

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: M-M-R II
Description: A single 0.5 mL subcutaneous injection at Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: PUVV
Description: A single 0.5 mL subcutaneous injection at Day 0
Study: NCT02184247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anhydrous theophylline, 350 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anhydrous theophylline, 300 mg
Study: NCT03561740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: additional metronomic chemotherapy of capecitabine
Study: NCT03608085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist Heart failure MTM training
Description: The MTM training for pharmacists will consist of:~1. Online material for home self-study (10 contact hours);~2. Didactic coursework to obtain a national American Pharmaceutical Association (APhA) MTM certification (8 contact hours); and HF pharmacotherapy (4 contact hours);~3. 1 60-minute sessions of point of care training in the community pharmacy practice lab setting by URI faculty;~4. Monthly coaching conference calls/webinars with URI and Brown Faculty;

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Heart failure MTM intervention
Description: The baseline visit will take place \>= 7 but \<= 30 days post discharge from the HF hospitalization. Follow-up visits will occur either in person at the patients local pharmacy or via telephone at 30, 60, 90 and 120 days post baseline and will consist of the following:~Preparation: Develop personal medication record (PMR). Assessment: Medication therapy reconciliation; Education: Review heart failure basics and behavioral goals Planning: Documentation of a medication related action plan and identify medication related problems Implementation: Communication of medication related action plan and changes in heart failure symptoms to the patients providers.~Follow up: Monitor and evaluate the care plan in collaboration with the patient's providers.
Study: NCT04693728

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resilient Intrinsic Self-Regulation Strategies in Extremes
Description: The manualized intervention covered resilience strategies organized into four modules: (1) engagement, (2) social relatedness, (3) transformation of pain and (4) building a good life. The modules were delivered in 8 weekly sessions of 90 minutes each.
Study: NCT01721239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Followup program
Description: Standardized written information, patient photos and three followup consultations.
Study: NCT02585167

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: operation
Description: the fistula will be excised after dividing the sphincter and primary reconstruction will be performed with absorbable sutures, closing the internal opening and leaving the external opening unclosed for drainage.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VAAFT
Description: Karl Storz Video Equipment is used. The fistula tract will be visualized from the external to the internal opening, closing the internal opening with absorbable sutures, then brushing and cauterization of the tract(s) leaving the external opening unclosed for drainage.
Study: NCT05205395

Intervention type: DIAGNOSTIC_TEST
Intervention: Transperineal ultrasound
Description: Ultrasonography was used with curved linear-array transducer placed between the major labia and underneath the external urethral orifice. The measurement was done on the midsagittal plane to obtain the image of pubic symphysis, urethra, and bladder in a view. Ultrasonic measurement of the overall rest-stress distance was define as the linear distance of bladder neck position change from resting status to maximal strain.
Study: NCT03010865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Butyrate
Description: Sodium butyrate is being supplied by T.E. Neesby (Brain White, T.E. Neesby, Inc.) in 730 mg capsules. The company asserts that their material is 98% pure and food grade. We will have identical placebo capsules. Subjects will receive 3 capsules twice daily (morning and late afternoon or evening) for a total of 4380 mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Placebo Oral Capsule is also being supplied by T.E. Neesby (Brain White, T.E. Neesby, Inc.) and there is no difference from appearance, smell and taste. It contains 1.5 mg sodium butyrate per capsule. Subjects will receive 3 capsules twice daily (morning and late afternoon or evening) for a total of 9 mg/day.
Study: NCT04280861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent Intervention
Description: Multicomponent intervention conducted by and expert psychologist that target different aspects of the caregiving experience (affective responses, communication skills, burden experience, social support and loneliness, cognitive performance, the practice of mindfulness and health-related behaviours). The number of sessions will be 8, 1 session of 90 minutes a week, and the number of participants will be 12-14 per group. In some sessions other collaborators will be invited to participate (social workers, physiotherapist).
Study: NCT02471742

Intervention type: PROCEDURE
Intervention: NAC-sparing mastectomy
Description: patients treated with mastectomy with conservation of nipple-areola complex

Intervention type: PROCEDURE
Intervention: NAC-sparing mastectomy
Description: patients treated with mastectomy with conservation of nipple-areola complex

Intervention type: PROCEDURE
Intervention: conventional mastectomy
Description: patients treated with mastectomy without conservation of nipple-areola complex
Study: NCT00770094

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Excimer Lasers
Description: WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment AMO/VISX CustomVue™ wavefront guided Excimer Laser System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Excimer Laser for the LASIK procedure
Description: WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment Bausch and Lomb Zyoptix™ wavefront guided Excimer Laser System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Excimer Laser for LASIK
Description: WaveLight ALLEGRETTO WAVE™ wavefront optimized excimer laser treatment Bausch and Lomb Planoscan™ Excimer Laser System
Study: NCT00549328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib (GW786034)
Description: Pazopanib monotherapy
Study: NCT03008577

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Change in ambient operating room temperature
Study: NCT00894647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imiquimod cream
Description: Imiquimod 3.75% cream (250 mg/packet) up to 2 packets applied daily Two 2-week treatment periods (Cycle 1 and Cycle 2) separated by a 2-week no-treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo cream
Description: cream applied once daily for two 2-week treatment periods (Cycle 1 and Cycle 2) separated by a 2-week no-treatment period
Study: NCT01913470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Oral tablet to be taken once daily at 0.4mg/kg/day (max 25mg) for one week and then increased to 0.8mg/kg/day (max 50mg) for 7 additional weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Oral tablet to be taken once daily at 0.4mg/kg/day (max 25mg) for one week and then increased to 0.8mg/kg/day (max 50mg) for 7 additional weeks.